Zimmer Biomet Holdings (ZBH): Sales Miss Was Disappointing But Now Its In The Stock - Leerink

November 1, 2016 7:05 AM EDT
Get Alerts ZBH Hot Sheet
Price: $104.45 --0%

Rating Summary:
    24 Buy, 14 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 17 | Down: 24 | New: 11
Trade ZBH Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Leerink Partners analyst, Richard Newitter, reiterated his Outperform rating on shares of Zimmer Biomet (NYSE: ZBH) but cut the price target to $136 from $150.

The analyst thinks ZBH’s 3Q sales miss was disappointing but considering the 14% pullback, with ZBH back at a ~6x P/E discount to the large cap MedTech avg., the valuation appears to be disconnected from the company’s double digit EPS growth prospects and longer-term mid single digit top-line potential.

For an analyst ratings summary and ratings history on Zimmer Biomet click here. For more ratings news on Zimmer Biomet click here.

Shares of Zimmer Biomet closed at $105.40 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Add Your Comment